Rolandic Epilepsy Genomewide Association International Study (REGAIN)

King's College London

Status: Completed

Conditions: Rolandic Epilepsy

Treatments: Other: Existing samples; Other: Blood draw

Study type: Observational

Funder types: Other

Identifiers

NCT03547050

229844

TWF 164-3020 (Other Grant/Funding Number)

Details and patient eligibility

About

We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.

Full description

Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 25% of child patients have "Rolandic Epilepsy" or RE, also known as Benign Epilepsy with Centrotemporal Spikes (BECTS). RE has a complex genetic basis, probably made up of combinations of susceptibility variants in different genes. Children with RE quite often have other symptoms that affect their speech, attention, reading ability or coordination. The goal of this study is to find the genetic basis for susceptibility to seizures and associated comorbidities for RE using genomewide association approaches.

We know that RE has a genetic basis and we recently discovered the genetic cause of the EEG pattern seen in RE. The goal of REGAIN is to now find the genetic basis for susceptibility to seizures and the associated symptoms above. Our hope is to be able to improve diagnosis and understand why each child with RE is different, and perhaps point us towards new treatments that are more effective and have fewer side effects.

We will compare the genetic code of 3,000 children with RE against a similar number of people not affected by epilepsy. With the proposed large sample of participants, we will be able to pinpoint the exact changes that might lead to seizures or attention problems for example. Learning the genetic basis for these problems will deepen our understanding of the mechanisms and lead to new treatments or cures.

Enrollment: 210 patients

Sex: All

Ages: 6 to 25 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosis of Rolandic Epilepsy in accordance with the following international criteria:

   • Age of first afebrile seizure 3-12 years
   • Seizures comprising focal sensorimotor seizures affecting the vocal tract and face, with or without involvement of the arm
   • Predominant sleep-related seizures
   • EEG interictal centro-temporal spikes with normal background

2. Current age 6-25 years

Exclusion criteria

1. No history of focal seizure
2. Normal EEG or abnormal background features on EEG
3. Known structural causes (stroke, tuberous sclerosis, infection, post-infectious or metabolic)
4. Primary diagnosis of autism or global learning disability
5. Focal central neurological deficit on clinical exam,
6. Unable to provide informed consent
7. Unable to provide blood sample

Trial design

210 participants in 2 patient groups

Patients diagnosed with RE

Description:

People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.

Treatment:

Other: Blood draw

Controls

Description:

People without a lifetime history of seizures.

Treatment:

Other: Existing samples